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Abstract
We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone
and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting
with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis,
a male patient was given a standard 3-day treatment course of Malarone®. Twenty-eight days later
the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01)
was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene
of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.
Introduction
Increasing reports of drug-resistant P. falciparum through-
out the world have forced changes in both prevention and
treatment. Malarone® (GlaxoSmithKline; atovaquone and
proguanil hydrochloride) is a recently introduced new
drug combination for the treatment [1,2] and prophylaxis
[3,4] of falciparum malaria. We report the first in vitro and
genetic confirmation of Malarone® resistance in a case of
P. falciparum acquired in Africa.
Case Report
A forty-five year old Nigerian male, resident in the UK,
presented with a fever and 1.5% P. falciparum parasitae-
mia two weeks after returning from a 4-week visit to La-
gos, Nigeria without taking prophylaxis. The patient was
given a standard 3-day treatment course of Malarone®;
four tablets daily (one tablet is equivalent to 250 mg of
atovaquone and 100 mg of proguanil hydrochloride)
with food which he tolerated well without vomiting and
was later discharged. Twenty-eight days later, his malaria
symptoms returned. After a further five days the patient
was readmitted to hospital with a parasitaemia of less
than 1 %. A blood sample taken at this point was placed
into culture. The patient was successfully treated with qui-
nine 600 mg three times per day for three days followed
by doxycycline 100 mg per day for seven days.
Drug sensitivity assays were performed at 1 % parasitae-
mia and 1 % haematocrit using tritiated hypoxanthine up-
take as a measure of parasite viability [5] and the isolate
(NGATV01) was shown to be resistant to atovaquone (Ta-
ble 1). The NGATV01 isolate was also resistant to the an-
tifolate pyrimethamine. The standard laboratory strain K1
was assayed as above and exhibited resistance to both
Published: 8 February 2002
Malaria Journal 2002, 1:1
Received: 19 December 2001
Accepted: 8 February 2002
This article is available from: http://www.malariajournal.com/content/1/1/1
© 2002 ; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this 
notice is preserved along with the article's original URL.Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/1
Page 2 of 4
(page number not for citation purposes)
Table 1: In vitro sensitivity of isolate NGATV01 and strain K1 to standard antimalarial drugs with standard deviations (nmol/L).
Drug NGATV01 K1 Resistance Cut-off*
   Mean IC50 ± SD Mean IC50 ± SD
Chloroquine    9.54 ± 1.18   133.29 ± 30.12 100
Mefloquine  24.14 ± 5.20    8.55 ± 0.29 20
Pyrimethamine  16012.80 ± 2643.55     8082.84 ± 1202.69 100
Atovaquone   1888.15 ± 106.65     2.41 ± 1.01 20
Proguanil   4205.50 ± 716.99 10239.94 ± 843.51 not determined
Dihydroartemisinin    2.39 ± 0.07     1.26 ± 0.46 not determined
Drug assay was performed at 1 % parasitaemia and 1 % haematocrit. Experiment was repeated twice in duplicate.* Cut-off points for resistance as 
previously reported [16,17,6]
Figure 1
Sequence analysis of P. falciparum CYT b gene from isolate NGATV01 showing codons 70 to 309. Residue 268 highlighted
shows the change from tyrosine (Y) to asparagine (N) compared to atovaquone-sensitive strain K1 and the change to serine (S)
in the atovaquone-resistant strain TM93-C1088 [6].
K1         SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109
TM93-C1088 SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109
NGATV01    SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109
K1         WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179
TM93-C1088 WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179
NGATV01    WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179
K1         FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249
TM93-C1088 FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249
NGATV01    FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249
K1         NTYVTPSQIVPEWYFLPFYAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309
TM93-C1088 NTYVTPSQIVPEWYFLPFSAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309
NGATV01    NTYVTPSQIVPEWYFLPFNAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309
K1         FGARD 314
TM93-C1088 FGARD 314
NGATV01    FGARD 314Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/1
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chloroquine and pyrimethamine. The DNA of NGATV01
was extracted and the cytochrome b coding region of mi-
tochondrial DNA (mtDNA) sequenced [6] in both direc-
tions together with DNA samples from P. falciparum
control strains. The sequence showed a change from TAT
to AAT in codon 268 (Figure 1), specifying a change from
tyrosine (Tyr) to asparagine (Asn): Y268N. A different mu-
tation in this codon leading to serine was reported earlier
in a sample (TM93-C1088) from an atovaquone and py-
rimethamine treatment failure in a Thai patient [6]
Discussion
The target of atovaquone, CYT b, plays an important role
in electron transport during mitochondrial respiration. It
is thought that the drug, an analogue of coenzyme Q (ubi-
quinone), interrupts electron transport and leads to loss
of the mitochondrial membrane potential [7,8]. Tyr268 is
a conserved bulky hydrophobic contact of the drug in the
Qo II region of the ubiquinol oxidation site. Substitution
of the less bulky Asn268 should affect the fit and binding
of the drug (Figure 2).
Resistance rapidly emerges when atovaquone is used
alone [9]. It has been hypothesised that the mode of ac-
tion of the drug might contribute to the rapid appearance
of resistant parasites. During a stage in its interaction with
the site when the drug is partially oxidised, the semiqui-
none formed would be capable of forming reactive oxy-
gen species (ROS) capable of acting as local mutagens
during replication of the mtDNA. Proguanil is believed to
speed the loss of the membrane potential, and ensure that
replication of DNA stops before mutagenesis can occur
[10].
Conclusions
This is an unusual example of resistance detected during a
single course of Malarone® on only a moderate parasitae-
mia. The atovaquone/proguanil combination has not
been widely used yet in West Africa so it is unlikely that
the patient was initially infected with an atovaquone-re-
sistant strain. The presence of multidrug-resistant strains
such as this example raises concern about the recent move
to consider using Malarone as first-line therapy in Africa
[11]. The case questions the potential useful life of this
combination, especially as atovaquone may persist alone
in plasma for up to 6 weeks after treatment [12]. It appears
that the synergistic interaction with proguanil is not seen
in atovaquone-resistant mutants [13], and higher resist-
ance levels are achievable.
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